Sugi Predict

Sugi Predict / Compounds / SCHEMBL970890

SCHEMBL970890

SCHEMBL970890

CC(C)(C)OC(=O)n1cc[c]n1

nearest known ligand 0.42

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ GPR119 Q8TDV5 8/20 0.36
▸ POLB P06746 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NR1H2 P55055 1/20 0.33
▸ BCHE P06276 1/20 0.33
▸ HTT P42858 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL971771 0.70 KDM4E (0.36) KMT2A
SCHEMBL1206559 0.68 NOS1 (0.44) USP2SMN1; SMN2GPR119POLBBCHE
SCHEMBL8136815 0.68 FAAH (0.36) USP2SMN1; SMN2GPR119POLBBCHE
SCHEMBL1908341 0.68 USP2 (0.38) USP2SMN1; SMN2GPR119POLBBCHE
SCHEMBL753707 0.67 GAA (0.43) USP2SMN1; SMN2MEN1KMT2ABCHE
SCHEMBL159357 0.66 BCHE (0.38) GPR119POLBMEN1KMT2ANR1H2
SCHEMBL2959354 0.66 BCHE (0.38) GPR119POLBMEN1KMT2ABCHE
SCHEMBL2013279 0.66 NOS1 (0.46) USP2GPR119MEN1KMT2ABCHE
SCHEMBL16060458 0.65 NR1H2 (0.37) POLBMEN1KMT2ANR1H2BCHE
SCHEMBL306662 0.64 HSP90AA1 (0.39) GPR119POLBMEN1KMT2ANR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110831926-B Tetrahydronaphtyl urea derivatives 持田制药株式会社 2023-11-21 — — CN disclosed
CN-109790148-B Cyano-substituted heterocycles having USP30 inhibitor activity 特殊治疗有限公司 2022-06-07 — — CN disclosed
US-10927079-B2 Intermediate compound of novel tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2021-02-23 — — US disclosed
US-20200239419-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2020-07-30 — — US disclosed
US-10669239-B2 Tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2020-06-02 — — US disclosed
EP-3617195-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES Mochida Pharmaceutical Co., Ltd. (JP) 2020-03-04 — — EP disclosed
CN-110831926-A Novel tetralinyl urea derivatives 持田制药株式会社 2020-02-21 — — CN disclosed
US-20190337897-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-11-07 — — US disclosed
US-10399945-B2 Tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-09-03 — — US disclosed
CN-109790148-A Cyano-substituted heterocycles having USP30 inhibitor activity 特殊治疗有限公司 2019-05-21 — — CN disclosed
WO-2011157682-A1 3-OXO-3,9-DIHYDRO-1H-CHROMENO[2,3-C]PYRROLES AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-22 — — WO disclosed
US-20110313002-A1 TRICYCLIC COMPOUNDS SARABU RAMAKANTH (US) 2011-12-22 — — US disclosed
CN-102007116-A Pyridazinone glucokinase activators HOFFMANN LA ROCHE 2011-04-06 — — CN disclosed
CN-102007118-A Pyrrolidinone glucokinase activators HOFFMANN LA ROCHE 2011-04-06 — — CN disclosed
US-20110021570-A1 PYRIDONE GLUCOKINASE ACTIVATORS HAYNES NANCY-ELLEN 2011-01-27 — — US disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 — — EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239419-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE CCNT2, UTS2R, DIMT1 USP2 1175/4885SMN1; SMN2 4203/4885GPR119 3141/4885
US-10927079-B2 Intermediate compound of novel tetrahydronaphthyl urea derivative CCNT2, DIMT1, QTRT2 USP2 2169/4885SMN1; SMN2 4338/4885GPR119 3051/4885
US-10399945-B2 Tetrahydronaphthyl urea derivative OPRL1, TRPV1, TSLP USP2 3129/4885SMN1; SMN2 1933/4885GPR119 687/4885
US-20190337897-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE UTS2R, OPRL1, TRPV1 USP2 2852/4885SMN1; SMN2 1656/4885GPR119 620/4885
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 USP2 4188/4885SMN1; SMN2 2392/4885GPR119 33/4885
US-20110021570-A1 PYRIDONE GLUCOKINASE ACTIVATORS GCK, PDXK, G6PD USP2 3644/4885SMN1; SMN2 2275/4885GPR119 39/4885
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK USP2 3928/4885SMN1; SMN2 2837/4885GPR119 35/4885
US-10669239-B2 Tetrahydronaphthyl urea derivative OPRL1, TRPV1, UTS2R USP2 3142/4885SMN1; SMN2 1681/4885GPR119 711/4885
US-20110313002-A1 TRICYCLIC COMPOUNDS GPR119, PC, GOT2 USP2 4064/4885SMN1; SMN2 3602/4885GPR119 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.